CS
EWTX icon

Candriam SCA’s Edgewise Therapeutics EWTX Stock Holding History

Candriam SCA’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1M Sell
447,416
-53,798
-11% -$1.55M 0.07% 232
2025
Q4 		$12.4M Buy
501,214
+280,055
+127% +$5.62M 0.06% 243
2025
Q3 		$3.59M Sell
221,159
-2,831
-1% -$40.2K 0.02% 407
2025
Q2 		$2.94M Sell
223,990
-1,806
-0.8% -$26K 0.02% 435
2025
Q1 		$4.97M Sell
225,796
-28,169
-11% -$739K 0.03% 329
2024
Q4 		$6.78M Sell
253,965
-40,659
-14% -$1.29M 0.04% 314
2024
Q3 		$7.86M Sell
294,624
-34,376
-10% -$684K 0.05% 298
2024
Q2 		$5.93M Hold
329,000
– – 0.04% 318
2024
Q1 		$6M Buy
329,000
+21,000
+7% +$334K 0.04% 311
2023
Q4 		$3.37M Buy
308,000
+10,000
+3% +$70.2K 0.02% 395
2023
Q3 		$1.71M Hold
298,000
– – 0.01% 471
2023
Q2 		$2.31M Hold
298,000
– – 0.02% 472
2023
Q1 		$1.83M Hold
298,000
– – 0.01% 594
2022
Q4 		$2.66M Buy
298,000
+108,000
+57% +$1.01M 0.02% 522
2022
Q3 		$1.87M Buy
+190,000
New +$1.92M 0.01% 594

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Candriam SCA's EWTX Position: Q1 2026 in Review

Candriam SCA reduced its Edgewise Therapeutics (EWTX) stake by 11% in Q1 2026, selling an estimated $1.55M and leaving 447,416 shares worth $14.1M. The position accounts for 0.07% of the portfolio, ranked #232.

Candriam SCA first reported a position in EWTX in Q3 2022 and has held it in 15 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Candriam SCA held 447,416 shares of Edgewise Therapeutics worth $14.1M as of Q1 2026.
  • Candriam SCA sold 53,798 Edgewise Therapeutics shares in Q1 2026, an estimated $1.55M.
  • Edgewise Therapeutics made up 0.07% of Candriam SCA's portfolio in Q1 2026, its #232 holding.
  • Candriam SCA first reported a position in Edgewise Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.